Accuray vs Inogen
Accuray reported revenue of $402 million in fiscal 2026, 1.2 times Inogen's $349 million in fiscal 2025. Accuray's revenue fell 12.3% in its latest year, and Inogen's grew 3.9%. Accuray had an operating margin of -6.6%, against -8.7% at Inogen. Free cash flow was −$13 million at Accuray and −$14 million at Inogen. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Accuray | Inogen | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $402M | $349M |
| Revenue growth | −12.3% | 3.9% |
| Revenue growth a year, last 5 years | 0.3% | 2.5% |
| Gross margin | 27.7% | 44.2% |
| Operating margin | −6.6% | −8.7% |
| Net margin | −12.2% | −6.5% |
| Free cash flow | −$13M | −$14M |
| Free cash flow margin | −3.2% | −3.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.3% | 12.5% |
| Last close | $2.12 | $5.42 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $134,146, sold $0 | sold $142,519 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AccurayInogen
Operating margin
Percent of revenue
AccurayInogen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AccurayInogen